Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Green tea shown to prevent prostate cancer

21.04.2005


First clinical study shows 90 percent efficacy in men with pre-malignant lesions



After a year’s oral administration of green tea catechins (GTCs), only one man in a group of 32 at high risk for prostate cancer developed the disease, compared to nine out of 30 in a control, according to a team of Italian researchers from the University of Parma and University of Modena and Reggio Emilia led by Saverio Bettuzzi, Ph.D.
Their results were reported here today at the 96th Annual Meeting of the American Association for Cancer Research.

"Numerous earlier studies, including ours, have demonstrated that green tea catechins, or pure EGCG (a major component of GTCs), inhibited cancer cell growth in laboratory models," Bettuzzi explained. "We wanted to conduct a clinical trial to find out whether catechins could prevent cancer in men. The answer clearly is yes."



Earlier research demonstrated primarily that green tea catechins were safe for use in humans. Bettuzzi and his colleagues had found that EGCG targets prostate cancer cells specifically for death, without damaging the benign controls. They identified Clusterin, the most important gene involved in apoptosis, or programmed cell death in the prostate, as a possible mediator of catechins action. "EGCG induced death in cancer cells, not normal cells, inducing Clusterin expression" said Bettuzzi.

To gauge susceptibility for prostate cancer among their research subjects, the team of Italian scientists recruited men with high-grade prostatic intraepithelial neoplasia – premalignant lesions that presage invasive prostate cancer within one year in nearly a third of cases and for which no treatment was given.

Eligible men were between 45 and 75 years of age. Vegetarians and men consuming green tea or derived products, or those taking anti-oxidants or following anti-androgenic therapy were excluded.

Of the 62 volunteers, 32 received three tablets per day of 200 mg each GTCs; the remainder were given a placebo. Follow-up biopsies were administered after six months and again at one year. Only one case of prostate cancer was diagnosed among those receiving 600 mg daily of GTCs, while nine cases were found in the untreated group. The 30 percent incidence rate among controls is consistent with previous findings, as was the absence of significant side effects or adverse reactions.

The interest in green tea catechins and other polyphenols – antioxidants found in many plants that give some flowers, fruits and vegetables their coloring – derives from traditional Chinese medicine, and the observation of lower cancer rates among Asian populations.

Bettuzzi observed that the Mediterranean diet is rich in vegetables, and lower rates of prostate cancer are found in that region, as well.

The 600 mg-per-day dosage of caffeine-free, total catechins (50 percent of which is EGCG) given to participants in the Italian study is one or two times the amount of green tea consumed daily in China, where ten to 20 cups a day is normal.

"We still don’t know enough about the biological processes leading to prostate cancer," Bettuzzi noted. "The only thing we know for sure is that prostate cancer is diffuse, related to age and more prevalent in the West. Thus, prevention could be the best way to fight it. Although our follow-up will continue for up to five years, a larger, confirmatory study is needed."

Even so, Bettuzzi hints at the exciting prospect of using green tea catechins as a prophylactic against prostate cancer in men believed to be at higher risk, such as the elderly, African-Americans, and those with a family history of prostate cancer.

Warren R. Froelich | EurekAlert!
Further information:
http://www.aacr.org

More articles from Health and Medicine:

nachricht Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht On track to heal leukaemia
18.01.2017 | Universitätsspital Bern

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Global threat to primates concerns us all

19.01.2017 | Ecology, The Environment and Conservation

Scientist from Kiel University coordinates Million Euros Project in Inflammation Research

19.01.2017 | Awards Funding

The Great Unknown: Risk-Taking Behavior in Adolescents

19.01.2017 | Studies and Analyses

VideoLinks
B2B-VideoLinks
More VideoLinks >>>